Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements

Hellenic Journal of Nuclear Medicine

Volumn 10, Issue 1, 2007, Pages 56-61

  Bantis, Athanasios ^a   Zisimopoulos, Athanasios ^b   Athanasiadou, Pavlina ^b   Gonidi, Maria ^b   Agelonidou, Eleni ^b   Strataki, Aphroditi ^b   Matthaios, Dimitrios ^b   Tsartsarakis, Antonios ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b NONE

Author keywords

Dihydrotestosterone; Free testosterone; Gonadotrophines; Luteinizing hormone; Prostate adenocarcinoma; Prostate specific antigen

Indexed keywords

ANDROSTANOLONE; FLUTAMIDE; FOLLITROPIN; GONADORELIN DERIVATIVE; GONADOTROPIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; FOLLITROPIN BLOOD LEVEL; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS FUNCTION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNORADIOMETRIC ASSAY; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEGATIVE FEEDBACK; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; RADIOIMMUNOASSAY; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

ADENOCARCINOMA; AGED; BIOLOGICAL MARKERS; DIHYDROTESTOSTERONE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TESTOSTERONE; TREATMENT OUTCOME;

EID: 34247898928     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Demers RV, Swanson M, Weis LK et al. Increasing incidence of cancer of the prostate. Arch Intern Med 1994; 154: 1211-1216.
2. Chodak G. Prostate cancer: Epidemiology, screening, and biomarkers. Rev Urol 2006; 8: S3-S8.
3. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I international comparisons. Brit J Urol 2002; 90: 162.
4. Hsing A, Tsao L, Devesa S et al. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60-67.
5. Greenle R, Murray T, Bolden S et al. Cancer statistics 2000. Cancer J Clin 2000; 50: 7-33.
6. Garfinkel L, Mushinski M. US cancer incidence, mortality and survival: 1973-1996. Stat Bull Metrop Insur Co 1999; 80: 23-32.
7. Massengill JC, Sun L, Moul JW et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670-1675.
8. Gleason DF. Histologic grading and clinical staging of prostate cancer. In: Urologic Pathology: The Prostate. Lea and Febiger: New York 1977; pp 171-198.
9. Scroder FH, Hermanek P, Denis L et al. The TNM classification of prostate cancer. Prostate 4 1992; (suppl): 129-138.
10. Clarke IJ, Cummins JT. Pulsatility of reproductive hormones: physiological basis and clinical implications. Baillieres Clin Endocrinol Metab 1987; 1: 1-21.
11. Kramer SA, Spahr J. Experience with Gleason histopathologic grading in prostatic cancer. J Urol 1980; 124: 223-229.
12. Raivio T, Santti H, Schatzl G et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 2003; 55: 194-198.
13. Miller L, Partin A, Daniel W et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998; 160: 449-453.
14. Oefelein M, Feng A, Scolieri M et al. Reassessment of definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 1021-1029.
15. Ross RK, Bernstein L, Lobo RA et al. 5-a-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887-889.
16. Hoffman MA, DeWolf WC, Morgentaler A et al. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-827.
17. Mohler J, Gregory C, Ford H et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res, 2004; 10: 440-448.
18. Belanger B, Belanger A, Labrie F et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. J. Steroid Biochem 1989; 32: 695-698.
19. Iversen P, Rasmussen F, Christensen IJ et al. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 1994; 157: 41-47.
20. Ernst DS, Hanson J, Venner PM et al. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol 1991; 146: 372-376.
21. Hoffman MA, DeWolf WC, Morgentaler A et al. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-827.
22. Schatzl G, Madersbacher S, Haitel A et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312-1315.
23. Lange P, Ercole C, Lighter J et al. The serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141: 873-879.
24. Ou YC, Chen JT, Yang CR et al. Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer. J Clin Oncol 2002; 32: 536-542.
25. Freedland SJ, Kane CJ, Presti JC et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol 2003; 169: 969-973.
26. Catalona WJ, Smith DS. Five-year tumor recurrence rates after anatomical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-1842.